Relay Therapeutics Inc (RLAY) - Net Assets
Based on the latest financial reports, Relay Therapeutics Inc (RLAY) has net assets worth $567.06 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($621.33 Million) and total liabilities ($54.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Relay Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $567.06 Million |
| % of Total Assets | 91.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -36.84% |
| 10-Year Change | N/A |
| Growth Volatility | 16.95 |
Relay Therapeutics Inc - Net Assets Trend (2018–2025)
This chart illustrates how Relay Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore RLAY total assets for the complete picture of this company's asset base.
Annual Net Assets for Relay Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Relay Therapeutics Inc from 2018 to 2025. For live valuation and market cap data, see RLAY stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $567.06 Million | -27.09% |
| 2024-12-31 | $777.79 Million | +3.43% |
| 2023-12-31 | $752.00 Million | -20.86% |
| 2022-12-31 | $950.22 Million | +5.84% |
| 2021-12-31 | $897.81 Million | +17.62% |
| 2020-12-31 | $763.29 Million | +523.02% |
| 2019-12-31 | $-180.44 Million | -62.66% |
| 2018-12-31 | $-110.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Relay Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 190059200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $168.00K | 0.03% |
| Other Comprehensive Income | $733.00K | 0.13% |
| Other Components | $2.58 Billion | 455.14% |
| Total Equity | $567.06 Million | 100.00% |
Relay Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Relay Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hap Seng Consolidated Bhd
KLSE:3034
|
$1.81 Billion |
|
Hunan TV & Broadcast Intermediary Co Ltd
SHE:000917
|
$1.81 Billion |
|
CSC Financial Co. Ltd
F:CS0
|
$1.81 Billion |
|
Zhejiang Jingu Co Ltd
SHE:002488
|
$1.81 Billion |
|
Globant SA
F:2G2
|
$1.81 Billion |
|
Shandong Pharmaceutical Glass Co Ltd
SHG:600529
|
$1.81 Billion |
|
Elkem ASA
OL:ELK
|
$1.81 Billion |
|
Wondershare Technology Co Ltd Class A
SHE:300624
|
$1.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Relay Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 777,792,000 to 567,060,000, a change of -210,732,000 (-27.1%).
- Net loss of 276,479,000 reduced equity.
- Share repurchases of 1,080,000 reduced equity.
- Other comprehensive income increased equity by 1,724,000.
- Other factors increased equity by 65,103,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-276.48 Million | -48.76% |
| Share Repurchases | $1.08 Million | -0.19% |
| Other Comprehensive Income | $1.72 Million | +0.3% |
| Other Changes | $65.10 Million | +11.48% |
| Total Change | $- | -27.09% |
Book Value vs Market Value Analysis
This analysis compares Relay Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.85x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-44.64 | $12.72 | x |
| 2019-12-31 | $-42.15 | $12.72 | x |
| 2020-12-31 | $8.46 | $12.72 | x |
| 2021-12-31 | $9.44 | $12.72 | x |
| 2022-12-31 | $8.47 | $12.72 | x |
| 2023-12-31 | $6.13 | $12.72 | x |
| 2024-12-31 | $5.44 | $12.72 | x |
| 2025-12-31 | $3.30 | $12.72 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Relay Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -48.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1800.58%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.10x
- Recent ROE (-48.76%) is below the historical average (-26.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.69 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-48.46 Million |
| 2020 | -6.87% | -63.41% | 0.10x | 1.05x | $-128.74 Million |
| 2021 | -40.53% | -12012.94% | 0.00x | 1.12x | $-453.65 Million |
| 2022 | -30.57% | -21036.13% | 0.00x | 1.16x | $-385.53 Million |
| 2023 | -45.47% | -1338.66% | 0.03x | 1.12x | $-417.17 Million |
| 2024 | -43.42% | -3374.72% | 0.01x | 1.12x | $-415.49 Million |
| 2025 | -48.76% | -1800.58% | 0.02x | 1.10x | $-333.19 Million |
Industry Comparison
This section compares Relay Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Relay Therapeutics Inc (RLAY) | $567.06 Million | 0.00% | 0.10x | $1.81 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more